GlassScriptPhysician profile
Micheal Odle
NPI 1386619369
$4,757.55
in general payments reported to CMS, 2019-2025
22 companies · $875 in 2025
The $875 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $34.94 · 2021: $1,026 · 2022: $1,063 · 2023: $796 · 2024: $964 · 2025: $875.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,362 · Travel and Lodging: $272.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,361.67 |
| Travel and Lodging | $272.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotronik INC. | $966.33 | 2021-2025 | Selectra, Acticor 7 Vr-T Dx, Biomonitor |
| Medtronic, INC. | $881.63 | 2021-2025 | Onyx Frontier, Cobalt Dr Mri Surescan, Na |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $457.29 | 2019-2025 | Lifevest |
| Abbott Laboratories | $411.09 | 2021-2024 | Xience Skypoint, Quartet, Coroflow |
| Novartis Pharmaceuticals Corporation | $407.39 | 2022-2025 | |
| Pfizer INC. | $285.34 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $271.25 | 2022-2025 | Eliquis, Camzyos |
| Astrazeneca Pharmaceuticals LP | $166.98 | 2021-2023 | Farxiga |
| Inari Medical, INC. | $155.18 | 2021-2022 | |
| Vital Connect, INC | $122.84 | 2023-2024 | Vitalpatch Rtm |
| Novo Nordisk INC | $110.72 | 2024-2025 | Wegovy |
| Daiichi Sankyo INC. | $95.80 | 2022-2024 | Injectafer |
| Amgen INC. | $74.82 | 2024-2025 | Repatha, Repatha |
| Merck Sharp & Dohme LLC | $69.84 | 2022-2023 | Verquvo |
| Boston Scientific Corporation | $52.83 | 2025 | Cds - Mct/Cem Monitoring |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $44.84 | 2022-2024 | Xarelto |
| Alnylam Pharmaceuticals INC. | $42.82 | 2024 | Onpattro |
| Chiesi USA, INC. | $38.43 | 2021-2022 | |
| Cvrx, INC. | $32.99 | 2022-2024 | Barostim Neo System |
| Lantheus Medical Imaging, INC. | $24.44 | 2024 | |
| Sanofi-Aventis U.S. LLC | $23.35 | 2024 | |
| Abiomed | $21.35 | 2024 | Impella |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Micheal Odle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.